New AI Tool Offers Detailed Cancer Prognosis and Recurrence …
WEBAug 19, 2024 · Researchers at NYU Langone Health's Perlmutter Cancer Center and the University of Glasgow developed a self-taught artificial intelligence (AI) tool for diagnosing adenocarcinoma.1 According to Aristotelis Tsirigos, PhD, the tool accurately distinguished between lung adenocarcinoma and squamous cell cancers 99% of the time and predicted cancer recurrence with 72% accuracy, outperforming ...
Phase 3 Trial of Tafasitamab in Follicular Lymphoma Meets …
WEBAug 16, 2024 · The pivotal phase 3 inMIND trial (NCT04680052) of tafasitamab-cxix (Monjuvi), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody in combination with lenalidomide (Revlimid) and rituximab (Rituxan) vs lenalidomide and rituximab alone in patients with relapsed or refractory follicular lymphoma (FL) met its primary end point of progression-free survival (PFS) by investigator ...
FDA-Approved and Investigational TRK Inhibitors - Targeted …
WEBJun 22, 2022 · 0:52 | Now, there are next-generation TRK inhibitors that are currently in clinical trials. Examples are selitrectinib, repotrectinib, and taletrectinib. These drugs are designed to target resistance mutations that might emerge with the first-generation agents. Alexander Drilon, MD, discusses targeted therapies for the patients with NTRK gene ...
FDA Acknowledges BLA of Zolbetuximab in HER2–, CLDN18.2
WEBMay 31, 2024 · The FDA has acknowledged the resubmitted biologics license application (BLA) for zolbetuximab (Vyloy) as a first-line treatment for locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive. Zolbetuximab is a first-in-class investigational CLDN18.2-targeted monoclonal antibody.
Enzalutamide Demonstrates Long-term Overall Survival in mHSPC
WEBJun 5, 2022 · After over 5 years of follow-up, enzalutamide (Xtandi) showed continued overall survival (OS) benefit in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to updated survival data presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. 1 In the 3-year update of the ENZAMET trial (NCT02446405), an international, cooperative group, phase 3 ...
Nadofaragene Firadenovec Continues to Demonstrate Durable …
WEBJan 17, 2024 · Findings from the phase 3 trial rAd-IFN-CS-003 (NCT02773849) continued to show ongoing durable clinical activity for nadofaragene firadenovec-vncg (Adstiladrin) in patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (± Ta/T1). 1 The 3-year data presented at the 2023 Society of Urologic Oncology ...
Treating Squamous vs Nonsquamous Disease - Targeted Oncology
WEBNov 15, 2013 · Treating Squamous vs Nonsquamous Disease. November 15, 2013. By Cheryl Zigrand. Publication. Article. Special Reports NSCLC (Issue 1) Volume 1. Issue 1. The addition of bevacizumab, erlotinib, afatinib, and crizotinib to the treatment arsenal for NSCLC has been a major advance in the treatment of this disease.
Actionable Mutations Playing and Increasingly Important Role in …
WEBApr 26, 2021 · Both KRAS and EGFR mutations have become increasingly important targets in non–small cell lung cancer (NSCLC). This is especially remarkable as KRAS was once considered an “untargetable mutation.”. The NSCLC space has seen major progress over the past few years, and it may be difficult to keep up …
Progression After R-CHOP: What Next? - Targeted Oncology
WEBMay 3, 2019 · Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Exposure to Agent Orange Associated With Increased Prevalence …
WEBMar 8, 2015 · Self-reported exposure to Agent Orange was significantly higher in patients with thyroid cancer (10.0%) than in those in the general VHA population (6.2%). The prevalence rate in veteran men (1:1023) was similar to that of the U.S. general population in 2011 (1:1219). The veteran women had a lower …